Slider
Pricing Table
Revitrox
- Considering just how serious the medical issue of hepatitis is, we’ve made sure to invent the drug that deals with this health hazard in the quickest and most efficient way!
Kodepin
- Due to just how serious the medical issue of bronchitis is, we’ve made sure to invent the drug that deals with this health hazard in the quickest and most efficient way!
Renalgin
- Because of just how serious the medical issue of hyperventilation is, we’ve made sure to invent the drug that deals with this health hazard in the quickest and most efficient way!
Testimonials
Call to action
With thousands of Research & Development
projects underway every year, we are doing everything humanly possible to make the world healthy again!
Images
Animated Counter
Toggles
Gastroenterology
ReHealth’s development programs in Gastroenterology are focused on advancing new treatments in constipation and diabetic gastroparesis. Key programs include low-dose and colonic release formulations for Linzess and relamorelin, a novel treatment for Diabetic Gastroparesis, a debilitating condition that has not had a new therapeutic option in more than 30 years.
Women’s Health
In Women’s Health and Urology, ReHealth is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray) as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.
Anti-Infectives
ReHealth’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections. Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia, as well as Aztreonam/Avibactam, a novel treatment for gram-negative infections. ReHealth is also focused on adding new innovative programs throughout its seven therapeutic areas.
Tabs
ReHealth’s development programs in Gastroenterology are focused on advancing new treatments in constipation and diabetic gastroparesis. Key programs include low-dose and colonic release formulations for Linzess and relamorelin, a novel treatment for Diabetic Gastroparesis, a debilitating condition that has not had a new therapeutic option in more than 30 years.
In Women’s Health and Urology, ReHealth is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray) as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.
ReHealth’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections. Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia, as well as Aztreonam/Avibactam, a novel treatment for gram-negative infections. ReHealth is also focused on adding new innovative programs throughout its seven therapeutic areas.
Contact Form
Audio
Solar Energy
Solar Energy
Solar Energy
Solar Energy
Maps
Toronto Office
Toronto Office
Social Sharing
Person
Mary Applebaum
Manager
A Juneau, Alaska native, Mrs. Applebaum has come a long way since her high school graduation all the way up to getting a Brown University Master’s degree in Economics. Talented with the digits, she’s no less successful when it comes to managing the human resources of the company. Ask anyone at our office who is their personal favorite manager…
Elisa Hansolo
Manager
Born in New York City, Elisa always felt a strong urge for being an ambitious overachiever. Eventually, by the age of 25 she already had received her first Wall Street executive position, making her one of the youngest managers in the company. With her overall work experience spanning over 2 decades…
Emily Bluesome
Manager
If you’d ask any of our workers, who is the executive manager that they’re always looking up and living up to, most likely Emily’s name will surface. Having a vast and thorough practical working experience lasting for more than 18 years, Mrs. Bluesome is an ideal manager, who is always on time to handle either our company’s clients…
Countdown Timer
Launching In
Launching In
Launching In
Launching In
Circles Counter
Client Satisfaction
New Service Ready
Clients back
Number Counter
Client Satisfaction
New Service Ready
Clients back
Accordion
Gastroenterology
ReHealth’s development programs in Gastroenterology are focused on advancing new treatments in constipation and diabetic gastroparesis. Key programs include low-dose and colonic release formulations for Linzess and relamorelin, a novel treatment for Diabetic Gastroparesis, a debilitating condition that has not had a new therapeutic option in more than 30 years.
Women’s Health
In Women’s Health and Urology, ReHealth is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray) as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.
Anti-Infectives
ReHealth’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections. Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia, as well as Aztreonam/Avibactam, a novel treatment for gram-negative infections. ReHealth is also focused on adding new innovative programs throughout its seven therapeutic areas.
Central Nervous System
In CNS, ReHealth is advancing programs to treat critical conditions such as Major Depressive Disorder (MDD), Migraine and Alzheimer’s disease. Key programs include rapastinel (MDD) Ubrogepant (Acute Migraine), M1, M4 and M1/M4 Agonists (Alzheimer’s disease) and an NR2Br Antagonist (OCD/Autism).